First-Year Roadmap 2026-2032 for Macao Medical Device Compliance

1. Key takeaways

The timeline of the Macao medical device regime is built from one effective date and three transition tracks: Law No. 12/2025 and Administrative Regulation No. 11/2026 both take effect on 1 July 2026; Article 65 sets transitional periods for medical devices already in circulation, expiring in three tiers by risk class and requiring an application at least one year before the transitional period expires; and Articles 66 and 67 set separate timelines for existing premises and existing manufacturing plants respectively. From implementation in 2026 until the last transitional period expires, the whole cycle spans roughly six years — companies should plan Macao compliance by calendar year rather than by project.

2. Legal basis

The instruments and provisions making up the transition timeline and the recurring compliance cycle are listed below.

3. Expert insights

Insight one: six years is not a licence to go slowly — three tracks run in parallel. The transition tracks for devices already in circulation, existing premises and existing manufacturing plants start at the same point but end at different times, and within each track the periods are tiered again by risk class. A company that operates, manufactures and sells products across several classes will hold six to eight different deadlines in its hands. Managing this with a single project plan will lose control; it should be managed with a compliance calendar.

Insight two: the at-least-one-year rule pulls the real deadline forward by a full year. Article 65 requires the application to be made at least one year before the transitional period expires. This means that for nominal expiry dates in 2029, 2030 and 2032, the real action deadlines are 2028, 2029 and 2031. Missing this rule is the most typical failure mode of transition-period compliance.

Insight three: review periods stack on top of the one-year rule. Class IIb takes 70 working days, Class III 100 working days, extendable by 45 working days, and before that comes the 20 working days of formal review under Article 13. Where inspection and deficiency correction are added, the actual period may far exceed one year. Practical estimate: treat the one-year rule as a minimum requirement, and reserve 18 to 24 months in the actual schedule.

Insight four: after the transition ends, the regime enters a recurring cycle. Registration is valid for 5 years, with a renewal window of 90 to 180 days before expiry; manufacturing licences run for 3 years, as do consensual manufacturing permits. The years 2026 to 2032 are the catch-up phase, and after 2032 comes the maintenance phase — the compliance organisation should shift from a project model to a standing operations model.

Insight five: in the first year, the most important thing to watch is the pace of new technical directives. ISAF has issued Dispatches No. 1 to 23 of the technical directive series, covering classification, clinical evaluation, GCP, exemption catalogue, name and labelling, dossiers, priority review, conditional approval, renewal, changes, third-party bodies, GMP and quality management system documentation, and consensual manufacturing. These directives will be revised more frequently than the law itself, and companies should set up a periodic review mechanism rather than reading them once and shelving them.

4. Practical recommendations

• Build a Macao compliance calendar: put all three transition tracks, every deadline and the one-year rule into the calendar.
• Schedule in tiers by risk class: Classes III and IIb first, then Classes IIa and I.
• Treat the one-year rule as the action deadline: do not schedule against the nominal expiry date.
• Reserve 18 to 24 months for the review cycle: covering the uncertainty of inspection and deficiency correction.
• Shift from projects to standing operations: build the team for the renewal cycles after 2032.
• Establish a periodic review of technical directives: check quarterly whether ISAF has published updates.

5. Verification checklist

• □ The start point and each end point of the three transition tracks have been confirmed (Articles 65, 66 and 67)
• □ Every SKU’s transitional expiry date and at-least-one-year reminder date are in the calendar
• □ The review cycle has been reserved at 20 + 70/100 + 45 working days
• □ The 5 working days of formal review for filings is built into the Class I and IIa schedules
• □ The 5-year validity of registration and the renewal window (90 to 180 days) are registered
• □ Renewal points for the 3-year manufacturing licence and 3-year consensual manufacturing permit are registered
• □ A quarterly review mechanism for the technical directives (Dispatches No. 1–23/ISAF/2026) is in place
• □ The standing compliance organisation for the period after 2032 has been planned

Legal information verified as of October 29, 2026. The laws, guidelines and effective dates described in this article are limited to the published content of the official sources listed under Legal basis as of that date; where official documents are updated, the most recently published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Macao, China. Our team manages adverse event reporting and recall coordination with the Health Bureau, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com